Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06899802 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
A Phase 2 study of Encephalitis, sponsored by Bavarian Nordic.
- Active
- Registry status
- Phase 2
- Development phase
- 411
- Enrollment target
- 9
- Study locations
NCT06899802: Active Phase 2 study of Encephalitis, sponsored by Bavarian Nordic.
NCT06899802 is a Phase 2 study of Encephalitis that is active but no longer recruiting, run by Bavarian Nordic. The registered enrollment target is 411 participants, below the 690-participant average among 4 other Encephalitis trials with a reported enrollment target (40% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06899802, a Phase 2 study of Encephalitis, is active but no longer recruiting, sponsored by Bavarian Nordic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 411 participants
- Enrollment target
- 9
- Study locations
Study Summary
This phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult participants of the recombinant, multivalent MVA-BN-WEV vaccine. MVA-BN-WEV is intended for active immunization for prevention of disease induced by VEEV and EEEV, in persons aged 18 years and older at high risk of exposure.
Primary Outcome
The participants' serum binding antibody titers of MVA-BN-WEV vaccine as measured by ELISA against EEEV and VEEV at 2 weeks after the second trial vaccination, and the participants' serum neutralizing antibody titers of MVA-BN-WEV vaccine as measured by PRNT against EEEV and VEEV at 2 weeks after the second trial vaccination.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL MVA-BN-WEV
Study Locations (9)
Missouri
- Jefferson City Medical Group / Avacare - Jefferson City
- Clay-Platte Family Medicine, P.C./CCT Research - Kansas City
California
- Benchmark Research - Sacramento
Georgia
- Lifeline Primary Care, Inc. / CCT Research - Lilburn
Kansas
- Johnson County Clin-Trials - Lenexa
Kentucky
- Versailles Family Medicine, PLLC/CCT Research - Versailles
Louisiana
- Benchmark Research - Kenner
Nebraska
- Papillion Research Center/CCT Research - Papillion
Texas
- Benchmark Research - San Angelo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
What the registry record for NCT06899802 still lists
NCT06899802 is an interventional study that assigns participants to a tested intervention. The registered 411 participants enrollment target is mid-sized for trials with a published cap, below the 690-participant average among 4 other Encephalitis trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Encephalitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06899802 lists 9 locations in 8 states (Missouri, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT06899802 about?
NCT06899802 is a clinical study titled "A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine". This phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult participants of the recombinant, multivalent MVA-BN-WEV vaccine. MVA-BN-WEV is intended for active immunization for prevention of disease induced by V...
What is the current status of trial NCT06899802?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 411 participants. The study started on 2025-03-10. Estimated completion is 2027-03.
What conditions does trial NCT06899802 study?
This clinical trial studies the following conditions: Encephalitis.
What interventions are being tested in trial NCT06899802?
The interventions under investigation include: Placebo (OTHER), MVA-BN-WEV (BIOLOGICAL).
Who is sponsoring clinical trial NCT06899802?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06899802 being conducted?
This trial has 9 study locations across California, Georgia, Kansas, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Encephalitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI